Epidermal growth factor receptor mutation (EGFR) testing for prediction of response to EGFR-targeting tyrosine kinase inhibitor (TKI) drugs in patients with advanced non-small-cell lung cancer : EGFR genetic testing and non-small-cell lung cancer

The mandate of the Medical Advisory Secretariat is to provide evidence-based policy advice on the coordinated uptake of health services and new health technologies in Ontario to the Ministry of Health and Long-Term Care and to the healthcare system. [...] Details of the technology’s diffusion into current practice and input from practising medical experts and industry add important information to the review of the provision and delivery of the health technology in Ontario. [...] Outcomes of Interest PFS ORR determined by means of the Response Evaluation Criteria in Solid Tumours (RECIST) OS QoL Quality of Evidence The quality of the Phase II trials and observational studies was based on the method of subject recruitment and sampling, possibility of selection bias, and generalizability to the source population. [...] The scope of this review will be limited to the evaluating the predictive value of EGFR mutation testing in the following conditions: Single-agent therapy with gefitinib compared with chemotherapy in the first-line setting; Single-agent therapy with gefitinib compared with chemotherapy in the second- or third-line settings; Single-agent therapy with erlotinib compared with best supportive ca [...] Differences in the direction of effect, the magnitude of the difference in effect, and the significance of the differences guide the decision about whether important inconsistency exists.